MedDataX Logo

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT ID: NCT07216482

Last Updated: 2026-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

975 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-11

Study Completion Date

2027-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C.

The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

NCT07300280

Healthy
ACTIVE_NOT_RECRUITING PHASE1

Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg

NCT00653445

Hypercholesterolemia Coronary Heart Disease Atherosclerosis
COMPLETED PHASE3

COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects

NCT00654485

Metabolic Syndrome
COMPLETED PHASE3

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

NCT00525824

Hypercholesterolemia Coronary Heart Disease Atherosclerosis
COMPLETED PHASE3

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

NCT00783263

Hypercholesterolemia
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enlicitide

Participants will receive enlicitide and a rosuvastatin-matching placebo. Both will be delivered orally once daily (QD) for up to 12 weeks.

Group Type EXPERIMENTAL

Enlicitide

Intervention Type DRUG

Oral Tablet

Placebo for Rosuvastatin

Intervention Type DRUG

Oral Capsule

Enlicitide + Rosuvastatin

Participants will receive enlicitide and rosuvastatin. Both will be delivered orally QD for up to 12 weeks.

Group Type EXPERIMENTAL

Enlicitide

Intervention Type DRUG

Oral Tablet

Rosuvastatin

Intervention Type DRUG

Oral Capsule

Rosuvastatin

Participants will receive rosuvastatin and an enlicitide-matching placebo. Both will be delivered orally QD for up to 12 weeks.

Group Type ACTIVE_COMPARATOR

Rosuvastatin

Intervention Type DRUG

Oral Capsule

Placebo for Enlicitide

Intervention Type DRUG

Oral Tablet

Placebo

Participants will receive an enlicitide-matching placebo and a rosuvastatin-matching placebo. Placebos will be delivered orally QD for up to 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo for Enlicitide

Intervention Type DRUG

Oral Tablet

Placebo for Rosuvastatin

Intervention Type DRUG

Oral Capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enlicitide

Oral Tablet

Intervention Type DRUG

Rosuvastatin

Oral Capsule

Intervention Type DRUG

Placebo for Enlicitide

Oral Tablet

Intervention Type DRUG

Placebo for Rosuvastatin

Oral Capsule

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-0616 Enlicitide decanoate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Has either not received lipid-lowering therapy (LLT) or has not received certain LLTs within a specified time period prior to the study.

Exclusion Criteria

* Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH.
* Had a heart failure hospitalization within 3 months before Screening.
* Is unwilling to take a statin, and/or has a history of statin-associated muscle symptoms or other statin-related AEs to any statin and dose, and/or is known to be intolerant to 1 or more statins.
* Has a history of any of the following conditions: (1) Myopathy, myositis, rhabdomyolysis, or unexplained muscle pain; (2) Muscular or neuromuscular disease; (3) Neuropathy, fibromyalgia, or chronic pain; or (4) Has a personal or family history of hereditary muscular disorders.
* Has active or chronic hepatobiliary or hepatic disease.
* Has known human immunodeficiency virus (HIV) infection.
* Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Screening or plans to initiate an LDL-C apheresis program.
* Has received any medication that may interact with rosuvastatin within 5 half-lives prior to Screening or is planning to initiate such treatment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Research Associates ( Site 0009)

Birmingham, Alabama, United States

Site Status RECRUITING

G&L Research ( Site 0024)

Foley, Alabama, United States

Site Status RECRUITING

Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030)

Phoenix, Arizona, United States

Site Status RECRUITING

Alliance for Multispecialty Research LLC ( Site 0049)

Tempe, Arizona, United States

Site Status RECRUITING

Chemidox Clinical Trials ( Site 0008)

Lancaster, California, United States

Site Status RECRUITING

Clinical Trials Research ( Site 0036)

Sacramento, California, United States

Site Status RECRUITING

Legacy Clinical Trials ( Site 0044)

Colorado Springs, Colorado, United States

Site Status RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0040)

Fort Myers, Florida, United States

Site Status RECRUITING

Soffer Health Institute ( Site 0046)

Hollywood, Florida, United States

Site Status RECRUITING

East Coast Institute for Research ( Site 0041)

Lake City, Florida, United States

Site Status RECRUITING

Inpatient Research Clinic ( Site 0017)

Miami Lakes, Florida, United States

Site Status RECRUITING

Clinical Research Trials of Florida ( Site 0001)

Tampa, Florida, United States

Site Status RECRUITING

Clinical Site Partners LLC, dba CSP Orlando ( Site 0014)

Winter Park, Florida, United States

Site Status RECRUITING

Trialmed ( Site 0026)

Chicago, Illinois, United States

Site Status RECRUITING

Great Lakes Clinical Trials - Ravenswood ( Site 0018)

Chicago, Illinois, United States

Site Status RECRUITING

Midwest Institute For Clinical Research ( Site 0033)

Indianapolis, Indiana, United States

Site Status RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0048)

Newton, Kansas, United States

Site Status RECRUITING

Cotton O'Neil Clinical Research Center ( Site 0006)

Topeka, Kansas, United States

Site Status RECRUITING

L-MARC Research Center ( Site 0004)

Louisville, Kentucky, United States

Site Status RECRUITING

Jubilee Clinical Research ( Site 0031)

Las Vegas, Nevada, United States

Site Status RECRUITING

Cardiovascular Associates of the Delaware Valley ( Site 0035)

Elmer, New Jersey, United States

Site Status RECRUITING

New Mexico Clinical Research & Osteoporosis Center, Inc. ( Site 0027)

Albuquerque, New Mexico, United States

Site Status RECRUITING

Alliance for Multispecialty Research, LLC - Norman ( Site 0043)

Norman, Oklahoma, United States

Site Status RECRUITING

Cardiology Consultants of Philadelphia Yardley ( Site 0016)

Yardley, Pennsylvania, United States

Site Status RECRUITING

Provecta Research Network LLC ( Site 0022)

Houston, Texas, United States

Site Status RECRUITING

Permian Research Foundation ( Site 0005)

Odessa, Texas, United States

Site Status RECRUITING

LinQ Research ( Site 0025)

Pearland, Texas, United States

Site Status RECRUITING

Clinical Trials of Texas, Inc. ( Site 0010)

San Antonio, Texas, United States

Site Status RECRUITING

Stone Oak, LLC dba Discovery Clinical Trials (DCT) ( Site 0021)

San Antonio, Texas, United States

Site Status RECRUITING

LinQ Research - Tomball ( Site 0047)

Tomball, Texas, United States

Site Status RECRUITING

Conquest Research ( Site 0045)

Arlington, Virginia, United States

Site Status RECRUITING

Manassas Clinical Research Center ( Site 0002)

Manassas, Virginia, United States

Site Status RECRUITING

Health Research of Hampton Roads, Inc. ( Site 0013)

Newport News, Virginia, United States

Site Status RECRUITING

National Clinical Research, Inc ( Site 0028)

Richmond, Virginia, United States

Site Status RECRUITING

Rainier Clinical Research ( Site 0023)

Renton, Washington, United States

Site Status RECRUITING

CEMEDIC ( Site 0201)

CABA, Buenos Aires, Argentina

Site Status RECRUITING

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0202)

Mar del Plata, Buenos Aires, Argentina

Site Status RECRUITING

CIPREC-CIPREC Sede Arenales ( Site 0200)

Buenos Aires, Buenos Aires F.D., Argentina

Site Status RECRUITING

Fundacion Estudios Clinicos ( Site 0203)

Rosario, Santa Fe Province, Argentina

Site Status RECRUITING

Instituto de Investigaciones Clinicas Rosario ( Site 0204)

Rosario, Santa Fe Province, Argentina

Site Status RECRUITING

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0206)

CABA, , Argentina

Site Status RECRUITING

Instituto de Cardiología "Juana F. Cabral"-Cardiología ( Site 0205)

Corrientes, , Argentina

Site Status RECRUITING

Australian Clinical Research Network ( Site 0900)

Maroubra, New South Wales, Australia

Site Status RECRUITING

Momentum Darlinghurst ( Site 0906)

Sydney, New South Wales, Australia

Site Status RECRUITING

Momentum Clinical Research Taringa ( Site 0907)

Taringa, Queensland, Australia

Site Status RECRUITING

Fusion Clinical Research ( Site 0901)

Norwood, South Australia, Australia

Site Status RECRUITING

Emeritus Research ( Site 0904)

Camberwell, Victoria, Australia

Site Status RECRUITING

Baker - HeartWest ( Site 0902)

Hoppers Crossing, Victoria, Australia

Site Status RECRUITING

Centro de Pesquisas em Diabetes e Doenças Endócrino-Metabólicas ( Site 0306)

Fortaleza, Ceará, Brazil

Site Status RECRUITING

Centro de Pesquisa Clinica do Coracao ( Site 0303)

Aracaju, Sergipe, Brazil

Site Status RECRUITING

Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0305)

Bragança Paulista, São Paulo, Brazil

Site Status RECRUITING

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0309)

São José do Rio Preto, São Paulo, Brazil

Site Status RECRUITING

IBPClin - Instituto Brasil de Pesquisa Clínica ( Site 0302)

Rio de Janeiro, , Brazil

Site Status RECRUITING

G A Research Associates ( Site 0102)

Moncton, New Brunswick, Canada

Site Status RECRUITING

Milestone Research Inc. ( Site 0111)

London, Ontario, Canada

Site Status RECRUITING

North York Diagnostic and Cardiac Centre ( Site 0110)

North York, Ontario, Canada

Site Status RECRUITING

Centricity Research Mirabel Multispecialty ( Site 0107)

Mirabel, Quebec, Canada

Site Status RECRUITING

Recherche Clinique Sigma Inc ( Site 0108)

Québec, Quebec, Canada

Site Status RECRUITING

Lausmed Egészségügyi Szolgáltató ( Site 1105)

Baja, Bács-Kiskun county, Hungary

Site Status RECRUITING

Borbánya Praxis ( Site 1103)

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Site Status RECRUITING

DRC Gyógyszervizsgáló Központ ( Site 1109)

Balatonfüred, Veszprém megye, Hungary

Site Status RECRUITING

Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Anyagcsere Tanszék) ( Site 1102)

Debrecen, , Hungary

Site Status RECRUITING

Barzilai Medical Center ( Site 0504)

Ashkelon, , Israel

Site Status RECRUITING

Linn Medical Center ( Site 0503)

Haifa, , Israel

Site Status RECRUITING

Rambam Health Care Campus ( Site 0500)

Haifa, , Israel

Site Status RECRUITING

Meir Medical Center. ( Site 0501)

Kfar Saba, , Israel

Site Status RECRUITING

Clalit Health Services - Sakhnin Community Clinic ( Site 0502)

Sakhnin, , Israel

Site Status RECRUITING

EAP Sardenya ( Site 0601)

Barcelona, , Spain

Site Status RECRUITING

EBA Centelles ( Site 0600)

Barcelona, , Spain

Site Status RECRUITING

Hacettepe Universite Hastaneleri ( Site 0700)

Sıhhiye, Ankara, Turkey (Türkiye)

Site Status RECRUITING

Eskisehir Osmangazi University ( Site 0705)

Eskişehir, , Turkey (Türkiye)

Site Status RECRUITING

İnönü Üniversitesi Turgut Özal Tıp Merkezi ( Site 0702)

Malatya, , Turkey (Türkiye)

Site Status RECRUITING

Velocity Clinical Research Romford ( Site 0803)

Bristol, Bristol, City of, United Kingdom

Site Status RECRUITING

West Walk Surgery ( Site 0801)

Yate, Gloucestershire, United Kingdom

Site Status RECRUITING

Velocity Clinical Research Havering ( Site 0804)

London, Havering, United Kingdom

Site Status RECRUITING

William Harvey Heart Centre ( Site 0800)

London, London, City of, United Kingdom

Site Status RECRUITING

Lakeside Surgery ( Site 0802)

Corby, Northamptonshire, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Canada Hungary Israel Spain Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Toll Free Number

Role: CONTACT

[email protected]
1-888-577-8839

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Coordinator

Role: primary

205-327-1077

Study Coordinator

Role: primary

251-943-2980

Study Coordinator

Role: primary

602-200-3814

Study Coordinator

Role: primary

602-910-3343

Study Coordinator

Role: primary

833-324-3643

Study Coordinator

Role: primary

916-487-8230

Study Coordinator

Role: primary

719-387-7572

Study Coordinator

Role: primary

239-936-4421

Study Coordinator

Role: primary

305-792-0555

Study Coordinator

Role: primary

386-463-5356

Study Coordinator

Role: primary

786-502-4303

Study Coordinator

Role: primary

813-873-8102

Study Coordinator

Role: primary

407-740-8078

Study Coordinator

Role: primary

877-469-4154

Study Coordinator

Role: primary

773-275-3500

Study Coordinator

Role: primary

317-705-7050

Study Coordinator

Role: primary

316-804-7301

Study Coordinator

Role: primary

785-368-0744

Study Coordinator

Role: primary

502-515-5672

Study Coordinator

Role: primary

702-631-5000

Study Coordinator

Role: primary

856-358-8125

Study Coordinator

Role: primary

505-855-5505

Study Coordinator

Role: primary

405-701-8999

Study Coordinator

Role: primary

215-321-7400

Study Coordinator

Role: primary

346-735-8990

Study Coordinator

Role: primary

432-368-6950

Study Coordinator

Role: primary

281-916-4220

Study Coordinator

Role: primary

210-949-0122

Study Coordinator

Role: primary

210-591-1154

Study Coordinator

Role: primary

281-351-6250

Study Coordinator

Role: primary

703-936-0761

Study Coordinator

Role: primary

703-330-1112

Study Coordinator

Role: primary

757-591-8100

Study Coordinator

Role: primary

804-755-2300

Study Coordinator

Role: primary

425-251-1720

Study Coordinator

Role: primary

+541146356624

Study Coordinator

Role: primary

+542234963224

Study Coordinator

Role: primary

5491144074402

Study Coordinator

Role: primary

+5403412221472

Study Coordinator

Role: primary

+5403414472217

Study Coordinator

Role: primary

+541148019001

Study Coordinator

Role: primary

5493794869598

Study Coordinator

Role: primary

+61414798280

Study Coordinator

Role: primary

02 8038 1044

Study Coordinator

Role: primary

+61735170520

Study Coordinator

Role: primary

+61413717245

Study Coordinator

Role: primary

+61395096166

Study Coordinator

Role: primary

61385321111

Study Coordinator

Role: primary

+55 85 996299242

Study Coordinator

Role: primary

+557930259700

Study Coordinator

Role: primary

+55 11 94202-3377

Study Coordinator

Role: primary

+55173201-5054

Study Coordinator

Role: primary

+552125277979

Study Coordinator

Role: primary

506-852-9865

Study Coordinator

Role: primary

519 659-4040

Study Coordinator

Role: primary

416-783-0000

Study Coordinator

Role: primary

4504200270x222

Study Coordinator

Role: primary

4185611165

Study Coordinator

Role: primary

0036705043288

Study Coordinator

Role: primary

+3642492170

Study Coordinator

Role: primary

+3687481616

Study Coordinator

Role: primary

+36 52 255 600

Study Coordinator

Role: primary

052-8945272

Study Coordinator

Role: primary

+97248568568

Study Coordinator

Role: primary

+97247772688

Study Coordinator

Role: primary

+97297472555

Study Coordinator

Role: primary

+972544719456

Study Coordinator

Role: primary

34935674385

Study Coordinator

Role: primary

+34938810485

Study Coordinator

Role: primary

0090 312 305 10 80

Study Coordinator

Role: primary

90 222 239 37 70

Study Coordinator

Role: primary

+904223410660

Study Coordinator

Role: primary

+44 117 4611208

Study Coordinator

Role: primary

+44 1454 272222

Study Coordinator

Role: primary

+44 1708 200 585

Study Coordinator

Role: primary

+442078823856

Study Coordinator

Role: primary

+441536748282

Related Links

Access external resources that provide additional context or updates about the study.

http://www.merckclinicaltrials.com

Merck Clinical Trials Information

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1319-9502

Identifier Type: REGISTRY

Identifier Source: secondary_id

2025-521495-54-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

MK-0616-037

Identifier Type: OTHER

Identifier Source: secondary_id

0616-037

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers
NCT02289430 COMPLETED PHASE1
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
NCT00862251 COMPLETED PHASE3
Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)
NCT00090298 COMPLETED PHASE3
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
NCT03019549 COMPLETED PHASE1
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)
NCT00651144 COMPLETED PHASE1
The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
NCT03288038 COMPLETED PHASE3
A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)
NCT00462748 COMPLETED PHASE3
Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients
NCT01164397 COMPLETED
A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men
NCT00549653 COMPLETED PHASE1
A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy
NCT04669041 COMPLETED PHASE3
A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)
NCT07222098 COMPLETED PHASE1
Effect of Rosuvastatin Therapy on HDL2 Level
NCT02593487 UNKNOWN PHASE4
Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
NCT04700436 COMPLETED PHASE4
Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome
NCT04056169 COMPLETED PHASE4
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
NCT02117453 COMPLETED PHASE3
Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases
NCT07313124 COMPLETED PHASE2/PHASE3
Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia
NCT03571087 COMPLETED PHASE3
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
NCT02516826 UNKNOWN PHASE2
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
NCT04862962 COMPLETED
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
NCT06186037 RECRUITING PHASE4
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
NCT00808678 COMPLETED PHASE1
Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects
NCT07309042 NOT_YET_RECRUITING PHASE1
Rosuvastatin and Evolocumab for Coronary Artery Disease
NCT05984953 COMPLETED
Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial
NCT04626973 COMPLETED NA
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
NCT04499859 RECRUITING PHASE4